VR Logo

Unicycive Therapeutics Inc. (UNCY) download report

Healthcare | Biotechnology & Pharma Research

Unicycive Therapeutics Inc. (UNCY) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Get the Stocks!

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.

IPO Date: 12-Jul-2021

Founder, Chairman, CEO & Pres: Dr. Shalabh K. Gupta M.D., MPA

Chief Financial Officer: Mr. John W. Townsend CPA

Listing: NASDAQ: UNCY

Country: United States

Headquarters: Los Altos, CA

Website: https://www.unicycive.com

Key Facts

Market cap: $12.32 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-12.59 Mln

Cash: $13.62 Mln

Total Debt: $0.30 Mln

Insider's Holding: 41.09%

Liquidity: Low

52 Week range: $0.64 - 8.73

Shares outstanding: 15,028,500

Stock Performance

Time Period Unicycive Therapeutics (UNCY) S&P BSE Sensex S&P Small-Cap 600
YTD-60.19-7.86-19.79
1 month-2.38-3.75-9.59
3 months-38.35-10.80-13.28
1 Year--1.50-17.92
3 Years--10.755.46
5 Years--11.435.57
10 Years--11.849.48
As on 06-Jul-2022
AMCs: